Cardiol Therapeutics Inc (CRDL)
Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
📈 **POSITIVE** • Medium confidence analysis (69%) • Strong positive catalyst • High growth potential **Sentiment:** Positive (95%) **Content type:** General